Y-mAbs Therapeutics Inc Investor Relations Material
Latest events
Q4 2023
Y-mAbs Therapeutics Inc
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Y-mAbs Therapeutics Inc
Access all reports
Y-mAbs Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. Our clinical programs are focused on DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.
Key slides for Y-mAbs Therapeutics Inc
Corporate Presentation
Y-mAbs Therapeutics Inc
J.P. Morgan 42nd Annual Healthcare Conference 2024
Y-mAbs Therapeutics Inc
Latest articles
The Three Cornerstones of Serial Acquirer Success
Explore what is behind successful serial acquirers: efficient capital use, decentralization, and a strong focus on people.
19 Apr 2024
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Puig's 2024 IPO: Paco Rabanne, Jean Paul Gaultier, and Beyond
Explore Puig's journey from its 1914 inception to a 2024 IPO, showcasing its growth, strategic acquisitions, and impact in the beauty and fashion industry.
15 Apr 2024
Ticker symbol
Country
đşđ¸ United States